Pacibekitug  (Synonyms: PF-04236921; TOUR-006)

Pacibekitug (PF-04236921; TOUR-006) is a fully humanized IgG2 monoclonal antibody targeting IL-6. Pacibekitug binds to and neutralizes IL-6 signaling, thereby inhibiting the pathophysiological role of this pro-inflammatory cytokine in autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, and systemic lupus erythematosus)^[1][2].

Human IgG2 kappa

Human IgG2 kappa, Isotype Control

Human

IL-6/IFNb2

PF-04236921 effectively inhibits the production of CRP, and its maximum inhibitory effect (Imax) is negatively correlated with baseline albumin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3569  [NCBI]

P05231

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.426 kDa

2948444-06-0

Liquid

colorless

[Pacibekitug]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG2-kappa

• 
  Immobilized IL-6 Protein, Human (HY-P7044) can bind Pacibekitug. The EC₅₀ for this effect is 6.84 ng/mL.

• [1]. Danese S, et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). Gut. 2019;68(1):40-48.  [Content Brief]

  [2]. Li C, et al. Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease. Br J Clin Pharmacol. 2018;84(9):2059-2074.  [Content Brief]